Inhibition of mTORC1 or ablation of SREBP1/SCD1 plays a protective role in ferroptosis in cancer cells with mutations in the PI3K-AKT-mTOR pathway, as well as enhances the effect of ferroptosis-induced cancer therapy. This evidence concerns the gene SREBF1 and cancer.